Related Experiment Video

Updated: Nov 29, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.2K

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous

Soha Namazi1, Ebrahim Sahebi2, Negar Azarpira3

  • 1Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Iranian Journal of Pharmaceutical Research : IJPR
|November 23, 2020
PubMed

Insights

This study found no link between ABCB1 gene variations and clopidogrel response in Iranian patients after percutaneous coronary intervention (PCI). Genetic factors did not significantly impact antiplatelet effectiveness in this population.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Clopidogrel is a key antiplatelet drug for preventing stent thrombosis after percutaneous coronary intervention (PCI).
  • Individual variability in clopidogrel response can lead to suboptimal antiplatelet effects, increasing risks.
  • The ABCB1 gene (ATP-Binding Cassette, Subfamily B, member 1) is implicated in drug transport and may influence clopidogrel efficacy.

Purpose of the Study:

  • To investigate the association between ABCB1 gene polymorphism and clopidogrel responsiveness in Iranian patients undergoing PCI.
  • To determine if genetic variations in ABCB1 affect platelet aggregation levels in response to clopidogrel.
  • To explore the influence of demographic factors on clopidogrel responsiveness.

Main Methods:

  • Sixty-seven Iranian patients undergoing PCI were enrolled.
  • Blood samples were collected at baseline, 2 hours, 24 hours, and 30 days post-clopidogrel loading dose.
  • Platelet aggregation was measured using light transmittance aggregometry (LTA) with adenosine diphosphate (ADP) stimulation.
  • ABCB1 genotyping was performed using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR).

Main Results:

  • The allelic frequencies for ABCB1 genotypes were: wild type (20.9%), heterozygote (74.6%), and homozygote (4.5%).
  • No statistically significant association was found between ABCB1 gene polymorphism and clopidogrel non-responsiveness.
  • Demographic characteristics did not show significant differences among patients.
  • Neither genetic nor demographic factors significantly affected platelet activity in response to clopidogrel.

Conclusions:

  • ABCB1 gene polymorphism does not appear to be a significant predictor of clopidogrel responsiveness in the studied Iranian population after PCI.
  • Genetic and demographic factors investigated did not significantly influence clopidogrel's antiplatelet effect in this cohort.
  • Further research may be needed to identify other factors contributing to clopidogrel variability in this population.

Keywords:
ABCB1 polymorphismClopidogrelP-glycoproteinPercutaneous coronary interventionResponsiveness

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.1K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.1K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
890
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
141
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
331
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
131
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
92